ArticleApplied and environmental microbiology2025
High prevalence of
Article in Applied and environmental microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Antimicrobial Resistance in Escherichia coli From Diagnostic Fecal and Uterine Samples of Swine in Northern Vietnam.Veterinary medicine and science · 2026Article
- Influence of housing system on antimicrobial resistance and population structure of extended-spectrum beta-lactamase-producing Escherichia coli in South Korean layer farms.Poultry science · 2026Article
- Molecular Epidemiology of theMicroorganisms · 2026Article
- Genomic Epidemiology of ESBL and Non-ESBL-ProducingAntibiotics (Basel, Switzerland) · 2026Article
- Restaurant occupational exposure affects the profiles of oral and gut pathobiomes and resistomes.Frontiers in microbiology · 2026Article
- Evolutionary trends and genetic determinants of third-generation cephalosporin resistance inFrontiers in microbiology · 2026Article
- ESBL-ProducingVeterinary sciences · 2025Article
- Can Improved Biosecurity Measures Reduce the Presence of the Most Common ESBL-ProducingLife (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The emergence of third-generation cephalosporin-resistant bacteria poses a significant human health hazard worldwide. We aimed to investigate the prevalence of extended-spectrum β-lactamase (ESBL)/AmpC β-lactamase-producing third-generation cephalosporin-resistant IMPORTANCE: Antimicrobial resistance in bacteria is a growing concern for both humans and animals. Pigs and their farm environment can carry and spread antimicrobial-resistant bacteria. Moreover, these resistant bacteria can be transmitted to humans and cause complications in treating infections. In this investigation, we present evidence for the widespread occurrence of third-generation cephalosporin-resistant extended-spectrum β-lactamase (ESBL)/AmpC β-lactamase (AmpC) genes in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.